Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Neola Medical’s CEO shares spring milestones and strengthened shareholder base in 2025 investor letter

Neola Medical

As 2025 unfolds, Neola Medical highlights key progress in clinical development and financing. The company has received approval from Swedish authorities to initiate its first clinical study on preterm born babies in Sweden and has completed a successful directed share issue of approximately SEK 20 million, strengthening its shareholder base with the addition of new institutional investors alongside existing shareholders.

“We have received approval from Swedish authorities to initiate our first clinical pilot study in Sweden, marking a major milestone as Neola® will be used for the first time on preterm born babies in neonatal intensive care. This achievement reflects years of development and our ability to navigate complex regulatory pathways. In parallel, we completed a successful directed share issue of approximately SEK 20 million, supported by new institutional investors, including Cicero Fonder and Adrigo Fonder, as well as existing shareholders, including Anmiro AB. Their participation complements our strong shareholder base and reflects long-term confidence in Neola Medical and our mission,” says CEO Hanna Sjöström.

Read more in the Investor letter spring 2025, attached to this press release and available on the company’s website www.neolamedical.com

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical’s CEO shares spring milestones and strengthened shareholder base in 2025 investor letter
Neola Medical Investor Letter Spring 2025

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.